fbpx

Day

februar 25, 2020
Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark – February 25, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of...

Nyheder

Fem unge medicinstuderende på forskningsophold i USA
9. juli 2020
Lundbeckfonden Ventures investerer i antidot mod blodfortyndere
8. juli 2020
Erfaren hjerneforsker i spidsen for The Brain Prize
30. juni 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge